AI Test Unlocks Precision Prostate Cancer Treatment, Saving Lives and Costs
Summary
A new AI test can identify which men with high-risk prostate cancer will benefit most from the life-extending drug abiraterone, potentially saving lives and NHS costs by avoiding unnecessary treatment for those unlikely to benefit.
Key Points
- A new AI test can identify which prostate cancer patients will benefit most from the life-extending drug abiraterone, potentially saving lives and reducing unnecessary treatment.
- For 25% of men with high-risk prostate cancer that hasn't spread, abiraterone nearly halves the risk of death when given alongside standard hormone therapy.
- The researchers urge NHS England to review its decision not to fund abiraterone for this group of men, as the drug is now cheaper and could save more money than it costs by preventing cancer relapses.